Innoviva (INVA) Set to Announce Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.5150 per share and revenue of $115.31 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Innoviva Trading Down 0.5%

NASDAQ:INVA opened at $20.94 on Wednesday. Innoviva has a 1-year low of $17.45 and a 1-year high of $25.15. The company’s fifty day moving average price is $20.99 and its 200-day moving average price is $21.83.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Zacks Research raised shares of Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Oppenheimer initiated coverage on Innoviva in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $35.00 price objective for the company. Weiss Ratings cut Innoviva from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Cantor Fitzgerald lowered their target price on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Finally, Wall Street Zen lowered Innoviva from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.25.

About Innoviva

Innoviva, Inc is a healthcare company focused on developing, commercializing and managing medicines, with an emphasis on respiratory and hospital-based therapies. The company’s business model includes royalty interests in marketed products as well as ownership and investment in companies developing or commercializing innovative treatments.

Innoviva receives royalty revenue from respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Relvar/Breo Ellipta.